What are the Endocrine Society recommendations for the pharmacological management of osteoporosis?

Updated: Jan 20, 2021
  • Author: Rachel Elizabeth Whitaker Elam, MD, MSc; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

A 2019 guideline from the Endocrine Society on pharmacological management of osteoporosis in postmenopausal women includes the following recommendations [247] :

  • Treat patients who are at high risk—particularly those with previous fracture.
  • Consider bisphosphonates as the first-line therapeutic choice for postmenopausal women at high risk of fracture.
  • Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
  • Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
  • Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
  • All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
  • Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!